UNILIFE CORPORATION (NASDAQ:UNIS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On June 8, 2017, the Board of Directors of Unilife Corporation (the “Company”) appointed Dennis Pyers, the Company’s Senior Advisor, Special Projects, as Interim Chief Financial Officer and Interim Chief Accounting Officer, effective as of June 9, 2017.  

Dennis Pyers, age 56, CPA, has served as our Senior Advisor, Special Projects, since July, 2016.  Prior to that, Mr. Pyers served as the Company’s Senior Vice President, Controller, Treasurer and Chief Accounting Officer since February 2015. From March 2014 to February 2015, he served as Vice President, Controller & Interim Chief Financial Officer and, from 2010 to 2014, he served as our Chief Accounting Officer, Vice President and Controller. Prior to that, from May 2009 to June 2010, Mr. Pyers served as an independent consultant, including as a consultant to us from May 2010 to June 2010. Before joining us, Mr. Pyers spent over twenty-five years with KPMG LLP, including serving as a partner from 2002 to 2009, providing a broad range of financial reporting, auditing, accounting and business advice to clients in the industrial markets and consumer products industries. He is a certified public accountant licensed in Pennsylvania, Maryland and New Jersey.

No material plan, contract, or arrangement was entered into or materially amended in connection with Mr. Pyers’ appointment as the Company’s Interim Chief Financial Officer and Interim Chief Accounting Officer, and there was no grant or award to Mr. Pyers or modification thereto under any such plan, contract, or arrangement in connection with such appointment. Mr. Pyers is not a party to any transaction that would require disclosure under Item 404(a) of Regulation S-K. There are no family relationships between Mr. Pyers and any of the Company’s directors or executive officers.

About UNILIFE CORPORATION (NASDAQ:UNIS)
Unilife Corporation is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies. The majority of its products are designed for sale directly to pharmaceutical and biotechnology companies supplying them as drug-device combination products, pre-filled and ready for administration by end-users, such as health-care providers or patients. Its other products, such as reusable auto-injectors and certain systems for targeted drug delivery are designed either to be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly to a health care provider or end user without having the device pre-filled by a pharmaceutical company.